We recently synthesized a panel of celastrol-based NR4A1 PROTAC degraders, some of which have outstanding efficiency in the degradation of NR4A1 in cancer cell lines as well as in syngeneic tumor models including B16 melanoma and MC38 colon cancer models. Here, NR4A1 is linked to malignant colon neoplasm.